摘要：In recent years the perception has arisen that biopharmaceuticals manufacturing capacity has gone from excess to shortage. What is the cause of this change and why were the shortfalls not addressed in time? This paper looks at how the structure of the industry has influenced the current shortfall and analyses the current manufacturing sector capacity and product mix. Looking to the future, the paper discusses factors that will dictate capacity requirements over the next five to ten years.
